Research digest · Melanocortin agonist
PT-141 is a melanocortin MC3R/MC4R agonist with a roughly 2.7-hour half-life and a single FDA-approved use.
A clinician's plain-spoken read of the bremelanotide literature — the mechanism, what the trials actually measured, and the tolerability picture surfaced first, every number carried back to its study.
The short version
PT-141 is the research name for bremelanotide, a lab-made peptide that acts on melanocortin MC3R/MC4R receptors (brain switches that influence sexual desire, appetite, and skin pigment). It is a real, FDA-approved prescription drug — but the approval covers exactly one use: low sexual desire that causes real distress in premenopausal women, a condition doctors call HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes marked personal distress). Every other use — in men, for erectile problems, in postmenopausal women, for "performance" — is off-label, and the male evidence is early-stage only. This page is a cited summary of what the studies found, not medical advice and not a dose to follow.
What Is PT-141?
PT-141 is a synthetic cyclic heptapeptide — seven amino acids joined in a ring — that copies the action of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural brain signaling peptide [1]. Its international nonproprietary name (INN), and the name on the approved injectable drug, is bremelanotide. The molecule weighs about 1,025 daltons and carries the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge that closes the ring and makes it more stable than the linear melanocortin peptides [1].
Unlike PDE-5 inhibitors (the erectile-blood-flow drugs such as sildenafil and tadalafil), which act peripherally on the smooth muscle of blood vessels, PT-141 works centrally — in the brain. It binds melanocortin receptors concentrated in the hypothalamus and limbic system and engages circuits tied to sexual motivation [1]. That central-versus-peripheral distinction is the single most important thing to understand about this compound, and it runs through everything below, from the PT-141 mechanism of action to the PT-141 side effects documented in trials.
PT-141 Peptide: A Melanocortin MC3R/MC4R Agonist
As a PT-141 peptide, the molecule is an agonist — an activator — at two central melanocortin receptors: MC4R (its primary target) and MC3R (secondary) [1]. These receptors sit in hypothalamic circuits, including the medial preoptic area, a region tied to sexual motivation [1]. Stimulating MC4R there is thought to recruit dopamine-driven pathways that govern desire and arousal rather than blood flow [1].
The same receptor family explains the compound's quirks. MC4R is also expressed in appetite circuits, which is why high-frequency dosing in early metabolic studies affected caloric intake and body weight — a pharmacological footnote, not an approved use [13]. And MC1R, a peripheral melanocortin receptor on pigment cells, is the basis for the skin and gum darkening seen with repeated dosing [13]. One receptor family; several distinct effects.
What the Approved Trials Measured
PT-141's approval rests on two identical Phase 3 randomized controlled trials known as RECONNECT (1,267 premenopausal women with HSDD) [3]. The 1.75 mg subcutaneous (injected just under the skin) as-needed dose met both coprimary endpoints: it improved sexual desire on the FSFI questionnaire (integrated change +0.35, P<.001) and reduced the distress that low desire causes on the FSDS-DAO scale (integrated item-13 change -0.33, P<.001) versus placebo over 24 weeks [3]. The standard questionnaires trials use — FSFI scores desire, FSDS measures the distress low desire causes — are how the field quantifies an outcome that is otherwise hard to measure.
Those results are statistically real and they were sustained over a 52-week open-label extension [4]. They are also, honestly, modest in size — a point critics have pressed [3]. This site reports both halves of that picture: see what the trials actually measured for the efficacy detail, and the PT-141 side effects documented in trials for the tolerability record, where nausea was the leading reason participants stopped [4].
Mechanism, Half-Life, and Tolerability — Where This Site Goes Next
PT-141 is delivered subcutaneously as a single as-needed dose, with a terminal half-life of about 2.7 hours after injection (range 1.9–4.0 h) and a median time to peak concentration near 0.5–1.0 hour [13]. The full pharmacokinetic story — distribution, clearance, why the experienced effect can outlast plasma levels — sits on PT-141 half-life and pharmacokinetics.
The tolerability record is foregrounded here because it is the part researchers most want straight. Over long-term use the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4], alongside a documented transient rise in blood pressure that makes the drug contraindicated in uncontrolled hypertension or known cardiovascular disease [13]. Read that record in full, including the cardiovascular and blood-pressure signal, and bring questions to the frequently asked questions about PT-141.